Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study
Mohammed Tarek Alam, Rubaiul Murshed, Pauline Francisca Gomes, Zafor Md. Masud, Mainul Sadia Saber, Mainul Alam Chaklader, Fatema Khanam, Monower Hossain, Abdul Basit Ibne Momen Momen, Naz Yasmin, Rafa Faaria Alam, Amrin Sultana, Rishad Choudhury Robin
European Journal of Medical and Health Sciences, doi:10.24018/ejmed.2020.2.6.599
I. BACKGROUND Submerged in the wave of Coronavirus disease 2019 (COVID-19), the world is weeping. Ever since the outbreak was first identified in December 2019 in Wuhan, China the world has not been the same [1] . An ongoing pandemic, the COVID-19 has proved to be the most devastating and unmanageable crisis the world has ever encountered. With the virus proudly lurking around in the atmosphere, millions of lives have already been compromised and many more uncountable innocents are still fighting to survive this war against the invisible rival. The call for an authentic treatment protocol against this virus was made long before
References
Adedokun, Olarinmoye, Mustapha, Kamorudeen, A close look at the biology of SARS-CoV-2, and the potential influence of weather conditions and seasons on COVID-19 case spread, Infectious Diseases of Poverty
Alam, Murshed, Bhiuyan, Saber, Alam et al., Case Series of 100 COVID-19 Positive Patients Treatedwith Combination of Ivermectin and Doxycycline, Journal of Bangladesh College of Physicians and Surgeons
Azeem, Ashraf, Rasheed, Anjum, Hameed, Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus, Pak J Pharm Sci
Baraka, Mahmoud, Marschke, Geary, Homeida et al., Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus, Eur J Clin Pharmacol
Caly, Druce, Catton, Jans, Wagstaff, The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Crump, Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations, J Antibiot
Crump, Ōmura, Ivermectin, 'wonder drug' from Japan: the human use perspective, Proceedings of the Japan Academy Series B, Physical and biological sciences
Götz, Magar, Dornfeld, Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Scientific Reports
Hopkins, Treating neglected tropical diseases, Community eye health
Ivermectin, Meyler's Side Effects of Drugs
Kylie, Sivakumaran, Steven, Harrich, David, Ivermectin is a specific inhibitor of importin α/βmediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochemical Journal
Lee, Lee, Ivermectin inhibits porcine reproductive and respiratory syndrome virus in cultured porcine alveolar macrophages, Archives of Virology
Lundberg, Pinkham, Baer, Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication, Antiviral Research
Lv, Liu, Wang, Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antiviral Research
Mastrangelo, Pezzullo, Burghgraeve, Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, Journal of Antimicrobial Chemotherapy
Merck, Over 30 Years: The Mectizan Donation Program
Msd, MECTIZAN Donation Program
Muñoz, Ballester, Antonijoan, Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers, PLoS neglected tropical diseases
Nguyen, Burton, Kuklinski, Gray, Foy, Ivermectin for the Control of West Nile Virus Transmission, New Horizons in Translational Medicine
Nguyen, Sakuna, Kinobe, Owens, Ivermectin blocks the nuclear location signal of parvoviruses in crayfish, Cherax quadricarinatus, Aquaculture
Nicholas, Rafael, Powell, A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection, Cell Host & Microbe
Raza, Shahin, Zhai, Ivermectin Inhibits Bovine Herpesvirus 1 DNA Polymerase Nuclear Import and Interferes with Viral Replication, Microorganisms
Satoshi, None
Sharun, Dhama, Patel, Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19, Annals of Clinical Microbiology and Antimicrobials
Tielsch, Beeche, Impact of ivermectin on illness and disability associated with onchocerciasis, Tropical Medicine & International Health
Varghese, Kaukinen, Gläsker, Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses, Antiviral Research
Wang, Lv, Wang, Qiu, Yang, Ivermectin treatment inhibits the replication of Porcine circovirus 2 (PCV2) in vitro and mitigates the impact of viral infection in piglets, Virus Research
DOI record:
{
"DOI": "10.3329/jbcps.v38i0.47512",
"ISSN": [
"1015-0870"
],
"URL": "http://dx.doi.org/10.3329/jbcps.v38i0.47512",
"abstract": "<jats:p>Background: A definitive treatment of SARS CoV-2 is yet to arrive and the human death toll rises exponentially globally. In this health emergency, it might be useful to look into the old therapies which could be effective against the virus. In vitro research showed Ivermectin could decrease the concentration of coronavirus 4000 to 5000 folds in living lung tissue.
\nAim: In this prospective study a combination of Ivermectin and Doxycycline will be evaluated therapeutically to treat COVID-19 patients. Methods: 100 COVID-19 patients were enrolled in this study with a predefined inclusion and exclusion criteria. RT- PCR of the SERS-CoV-2 will be done at designated government hospitals. The clinical features and response to treatment were noted according to a dedicated protocol.
\nResults: In this study male and female were 64 and 36 respectively, the age ranged between 8 to 84 years. Retesting was done between 4 and 18 days of starting medication. All patients tested negative and their symptoms improved within 72 hours. There were no noticeable side effects.
\nConclusion: Combination of Ivermectin and doxycycline was found to be very effective in viral clearance in mild and moderately sick COVID-19 patients. Medical societies and institutions should undertake larger multi center studies to validate and recommend this combination therapy to include in national guidelines.
\nJ Bangladesh Coll Phys Surg 2020; 38(0): 10-15</jats:p>",
"author": [
{
"affiliation": [],
"family": "Alam",
"given": "Mohammed Tarek",
"sequence": "first"
},
{
"affiliation": [],
"family": "Murshed",
"given": "Rubaiul",
"sequence": "first"
},
{
"affiliation": [],
"family": "Bhiuyan",
"given": "Elias",
"sequence": "first"
},
{
"affiliation": [],
"family": "Saber",
"given": "Sadia",
"sequence": "first"
},
{
"affiliation": [],
"family": "Alam",
"given": "Rafa Faaria",
"sequence": "first"
},
{
"affiliation": [],
"family": "Robin",
"given": "Rishad Choudhury",
"sequence": "first"
}
],
"container-title": "Journal of Bangladesh College of Physicians and Surgeons",
"container-title-short": "J. Bangladesh Coll. Phys.",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2020,
7,
31
]
],
"date-time": "2020-07-31T13:35:25Z",
"timestamp": 1596202525000
},
"deposited": {
"date-parts": [
[
2020,
7,
31
]
],
"date-time": "2020-07-31T13:35:32Z",
"timestamp": 1596202532000
},
"indexed": {
"date-parts": [
[
2024,
5,
14
]
],
"date-time": "2024-05-14T18:02:15Z",
"timestamp": 1715709735109
},
"is-referenced-by-count": 36,
"issued": {
"date-parts": [
[
2020,
6,
12
]
]
},
"link": [
{
"URL": "https://www.banglajol.info/index.php/JBCPS/article/download/47512/34879",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://www.banglajol.info/index.php/JBCPS/article/download/47512/34879",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "1861",
"original-title": [],
"page": "10-15",
"prefix": "10.3329",
"published": {
"date-parts": [
[
2020,
6,
12
]
]
},
"published-online": {
"date-parts": [
[
2020,
6,
12
]
]
},
"publisher": "Bangladesh Journals Online (JOL)",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.banglajol.info/index.php/JBCPS/article/view/47512"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline",
"type": "journal-article"
}
